PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Bone. Author manuscript; available in PMC Apr 11, 2011.
Published in final edited form as:
PMCID: PMC3073451
NIHMSID: NIHMS146505
Notch Signaling and the Bone Marrow Hematopoietic Stem Cell Niche
Jonathan M. Weber and Laura M. Calvi
Endocrine Division, Wilmot Cancer Center, Department of Medicine and Center for Musculoskeletal Research, University of Rochester School of Medicine, Rochester NY
Address correspondence to: Laura M. Calvi, Endocrine Division, Department of Medicine, University of Rochester School of Medicine, 601 Elmwood Avenue Box 693 Rochester 14642 NY USA, Tel (585) 275-5011; Fax (585) 273-1288; laura_calvi/at/urmc.rochester.edu
Recently there has been increased interest in the regulatory interactions between osteoblasts and cells in the surrounding bone marrow microenvironment. The proximity of hematopoietic stem cells (HSCs) with osteoblastic cells first suggested regulatory interactions and recent data have highlighted the role of osteoblastic cells in providing a HSC niche. Reports have indicated that direct contact is necessary to mediate the osteoblastic effects and that these effects could be mediated through Notch activation. Notch signaling is important throughout development and also appears to play a critical role in cellular maturation and differentiation of osteoblastic cells and hematopoietic cells as disregulation can lead to bone loss and leukemias respectively. In this review we discuss the current understanding of Notch signaling and how it functions in hematopoiesis, osteoblastic cells, and the interactions between HSC and their osteoblastic niche.
In the late 70’s Schofield used the term niche to define custom microenvironments composed of subset of cells and extracellular substrates required to support localization, survival, and self-renewal of stem cells in vivo [1]. Conceptually the niche can be thought of as a region that can harbor stem cells and maintain balance between self renewal and differentiation. Over the years, a body of evidence has accumulated in a number of animal models which supports the concept of microenvironmental regulation of stem cells [2]. Notch signaling is in many ways ideal for instructive communication between the niche and stem cells as it is highly conserved, requires direct contact of adjacent cells, and Notch signaling can influence cell fate decisions [3]. While HSCs are fairly well understood, only recently data have indicated cellular and molecular components of the bone marrow HSC niche [4], with some of the first evidence suggesting that osteoblastic cells are supportive of HSCs coming from in vitro work [5]. The important role of Notch signaling in hematopoiesis was highlighted by its association with hematological malignancies [6, 7], which initiated a great deal of interest in the role of Notch signaling in HSC regulation and in hematopoietic lineage allocation and differentiation, as we will review. Most recently, in vivo evidence has strongly implicated Notch signaling in regulation of osteoblastic differentiation [8] [9]. Together, these lines of investigation would suggest that Notch signaling in the bone marrow microenvironment could be essential in HSC-osteoblastic regulatory interactions, and in fact, data defining the role of osteoblastic cells in HSC regulation point to Notch signaling as a potential intermediary [10]. In this review we will discuss the Notch signaling pathway and how it functions in the hematopoietic system, osteoblastic cells, and the interaction between HSC and their microenvironment which have emerged so far.
The canonical Notch Signaling pathway is highly conserved and plays roles in many cellular functions including cellular growth, differentiation, and fate choices [3]. In mammals four Notch receptors (Notch 1–4) and five ligands (Jagged1-2 and Delta like 1, 3, and 4) have been identified, all of which are single span transmembrane proteins that require cell-cell contact for activation [11]. When a Notch ligand comes in contact with Notch, the external portion of Notch is cleaved by tumor necrosis factor (TNF) -α-converting enzyme, a member of the ADAM metalloprotease family. A second intracellular cleavage event occurs through the γ-secretase complex, which releases the activated Notch intracellular domain (NICD) which initiates the signal. Presenilin (PS) 1 and 2, nicastrin, APH1 and PEN2 form the complex which has γ-secretase activity[12]. After the NICD has been cleaved it can translocate to the nucleus and bind to CSL (CBF1 in humans, RBPJ in mice, Suppressor of hairless in Drosophila, Lag1 in C. elegans), which turns it from a repressor to activator by displacing corepressor complexes [1315], and recruiting coactivators such as Mastermind-like (MAML) proteins [16, 17]. Canonical downstream signals of Notch include HES1 and HES5 and Hey1.
1. Notch, Leukemias and Hematopoietic Lineage Allocation
Strong evidence for the role of Notch signaling in hematopoiesis is provided by the finding that aberrations in Notch can lead to leukemias. Notch was first linked to T-cell neoplasias in the late 80’s and early 90’s with the identification of the t (7;9) chromosomal translocation which was cloned from a subset of T-cell acute lymphoblastic leukemias (T-ALL) [6, 7]. This translocation resulted in a truncated form of Notch1 termed translocation associated Notch homolog (TAN1), which correlates to the activated NICD. When bone marrow was retrovirally transduced with TAN1 50% of the mice developed T-ALL with similar presentation to the human disease [18]. Additional studies with the dominant active forms of Notch receptors in hematopoietic progenitor cells or immature thymocytes also induced development of T-cell leukemias [1820]. In a study conducted on pediatric cases of T-ALL over 50% of the subjects had a Notch mutation [21]. Further studies have suggested that that Notch signaling in the thymic microenvironment also plays a role in T-cell/B-cell lineage commitment [22].
Notch has been implicated in many lymphoid leukemias but there have been only a few reports of Notch mutations in myeologenous leukemias, where it is unclear whether the Notch abnormalities caused the leukemia [23]. However, some studies have demonstrated Notch effects on myelopoiesis, with Notch ligands suppressing myeloid differentiation of progenitor cells [24]. Together, these data of effects of Notch signaling in both lymphoid and myeloid lineages suggest that Notch signaling may be involved in hematopoietic lineage allocation and differentiation. These Notch effects have been extensively reviewed elsewhere [25, 26].
2. Notch and HSC
In an effort to test Notch signaling’s effect on HSC, Varnum-Finney et al. transduced lineage negative (lin-), c-kit positive, sca-1 positive cells (LSK), which represent a population phenotypically enriched for HSC, with the active Notch1 intracellular domain (N1ICD) [27]. Compared with untransduced cells, which were no longer viable by 25 days, the cells transduced with N1ICD continued to maintain an undifferentiated appearance and proliferate for over 8 months, suggesting that Notch activation increases HSC self-renewal. In vivo transplant studies with these cells showed that repopulation could occur in all blood lineages although B-cell reconstitution was reduced, consistent with a Notch effect also on lineage allocation. Interestingly, if the transduced LSK were transplanted without other cells, the animals would die after two weeks, indicating that Notch1 activation kept HSC in either a more immature state and prohibited them from differentiating into mature cells or that they could not enter into the periphery [27]. In a similar study, Stier et al transduced lin- sca-1+ cells with activated Notch1. They found that Notch1 activation inhibited differentiation of HSC both in vitro and in vivo by impeding the differentiation of stem cells from the progenitor pool resulting in an increase of HSC which was confirmed by secondary transplantation experiments [28]. Taken together, these results suggest that Notch signaling maintains and may expand HSCs.
To identify and quantify Notch activation in vivo transgenic Notch reporter (TNR) mice were generated, which express GFP when Notch signaling is activated [29]. The LSK compartment from the TNR mice had a higher percentage of GFP expression than their progeny, which indicates that Notch signaling is active in more undifferentiated populations. LSK that were either GFP+ or GFP− formed the same number of colonies (CFU-C), but the GFP+ LSK had significantly more multiple cell type colonies, suggesting that these cells were multipotent and more undifferentiated. These results were also confirmed in vivo when GFP+ LSK were transplanted into irradiated recipients and had a greater long term reconstitution as demonstrated by secondary transplantation experiments [30]. Additionally transplanted Notch-inhibited HSC were found to deplete the HSC pool as they preferentially differentiated instead of undergoing self renewal [29]. Using GFP+ LSK from TNR mice this group was also able to demonstrate that the precursors divide symmetrically in a prorenewal environment and asymmetrically in prodifferentiation environment [30]. Again, these data suggest that Notch signaling maintains and expands the most primitive HSC.
Thus, Notch-related data generated so far in general support the concept that Notch signaling affects stem cell regulation by favoring self renewal over differentiation [28].
1. In vitro Studies
Many independent studies have established that Notch1 and the Notch ligands Jagged1 and Delta-like1 are expressed in osteoblasts [10, 3136]. In vitro studies attempting to elucidate the role of Notch signaling in bone have led to contradictory conclusions that Notch activation either impairs [32, 33, 3739] or facilitates [34, 40, 41] osteoblastic differentiation. The disparity in these studies could be due to different cellular models, different stages of differentiation when cells were used for experimentation, as well as the stable or transient transfection of Notch signaling elements. Although the in vitro studies do not offer conclusive evidence about the role of Notch signaling in osteoblastic cells, it is it apparent that Notch signaling has important effects on osteoblastic cells. Some of the contradiction in the in vitro results may stem from the likely possibility that Notch may play different roles depending on the maturation stage of the osteoblastic cell, as it does in other biological systems.
2. In vivo Studies
Recent in vivo studies gave us more insight into the role of Notch signaling in bone using genetic models with Notch signaling elements altered at different stages of differentiation. Engin et al. overexpressed the N1ICD under the control of the type I collagen (Col1α 1) promoter and found that genetically altered animals had an osteosclerotic phenotype with thickened bone mass and a marrow cavity filled with trabecular bone [8]. Additionally, all Notch signaling was removed in vivo from osteoblastic cells by targeted deletion of the required components of the γ-secretase complex. Presenilin1/2 (PS1/2) are components of the γ-secretase complex that cleaves and activates the NICD. A mouse model was generated in which Presenilin2 is globally deleted and Presenilin 1 is selectively removed from osteoblastic cells only (Col1α1cre/+ PS1fl/fl PS2 −/− mice) [8]. Previous studies had demonstrated that removal of both Presenilins completely abolishes NICD production [42], however, since γ-secretase activity also plays a major role in cleaving and regulation the amyloid precursor protein to form β-amyloid proteins as well as Cadherins and other proteins [42], the results from these animals must be interpreted in the context of other Notch genetic models. Col1α1cre/+ PS1fl/fl PS2 −/− mice appeared normal at 3 months compared to littermate controls (PS1fl/fl PS2 −/−), but developed an osteoporotic phenotype at 6 months. These results suggest that loss of canonical Notch signaling led to osteoporosis through activation of osteoclastogenesis (see below) and increased bone resorption compared to formation rates with age[8].
Hilton et al. also used the PS1fl/fl and PS2 −/− mice, but crossed them with a Prx1 cre, which is expressed earlier, at the stage of mesenchymal stem cells (MSCs) [9]. The Prx1cre/+ PS1fl/fl PS2 −/− mice had shorter, denser long bones than controls (PS1fl/fl PS2 −/−) at eight weeks but died unexpectedly at 9–10 weeks of age from unknown causes. The Prx1cre/+ mice were also mated with Notch1−/fl Notch2 fl/fl mice (PNN) with the hope that these animals would survive through adulthood. These animals had a similar phenotype at 8 weeks to the Prx1cre/+ PS1fl/fl PS2 −/− with increased bone mass and trabecular bone in the marrow cavity. Interestingly by 15 and 26 weeks the PNN mice lost the increased bone mass which was reduced to a level far below the control animals, likely also due to effects on osteoclasts [9].
Similar to some of the in vitro results, these two studies report contrasting data which is very likely due to Notch’s divergent roles at different stages of differentiation. An example of opposite effects of Notch signaling depending on differentiation stage is provided by neuronal differentiation. In neuronal development Notch signaling has been well characterized and is either required to be up or down regulated in order for certain cells types to form during differentiation [43]. It is likely that Notch signaling works in a similar fashion in osteoblastic differentiation. It appears that Notch signaling is important for maintaining osteoblastic progenitors because removal from MSCs results in a short term dramatic increase in bone. Therefore Notch signaling could be used to maintain a progenitor population and also be involved in terminal differentiation. We can also speculate that Notch signaling in mature or terminally differentiating osteoblastic cells might ultimately feedback on the MSC population and call for further self renewal. Additionally, both these studies suggest that Notch signaling may play a further role in bone homeostasis by having direct effects on osteoclasts. Additional data have suggested an important role of Notch signaling in osteoclastic differentiation and activation [44, 45]. Further investigation into these models and direct comparison of developmental activation and inactivation of Notch signaling is necessary to determine the mechanisms by which Notch signaling alters osteoblastic maturation and bone maintenance.
As a system providing rapid environmental cell-initiated signals to stem cells, the Notch signaling pathway would be predicted to play an important role in stem cell niches. In fact, much data support the role of Notch signaling as a key mediator of niche-stem cell interactions in a number of organisms and in numerous organ systems. For example, Notch is reported to be important in gonadal niches in both worms [46] and flies [47, 48], where Notch signaling may also determine niche size. In the murine heart, cardiac progenitor cells express Notch1, while supporting cells express Jagged1, and Notch activation regulates early fate choices in cardiac progenitor cells [49]. Thus, a strong precedent exists for Notch ligands in the microenvironment to initiate regulatory Notch activation in stem cells.
Examples exist of the importance of Notch signaling in relaying instruction from the microenvironment to stem cells in numerous systems, but what about mammalian HSCs? Mammalian HSCs are some of the best characterized stem cells. One of the difficulties in determining the signals involved in HSC regulation by the microenvironment has been that the cellular regulatory components of the bone marrow microenvironment have only recently come to light. Currently the HSC niche is thought to be comprised of either osteoblastic cells [10, 50, 51], endothelial cells (reviewed in Colmone et al. [52]), or potentially both. As we have already discussed, Notch signaling has been shown to play roles in both HSC regulation and in osteoblastic cells. Multiple in vitro studies have demonstrated that cells expressing Notch ligands or plates with immobilized Notch ligands can maintain or enhance HSC self renewal in culture [5359]. The in vitro studies all show a Notch-dependent consistent increase in HSCs, but as we review below the growing body of evidence studying in vivo Notch signaling between HSCs and the bone marrow microenvironment remains contradictory.
The Notch ligand Jagged1 is expressed in bone marrow stromal cells [53, 60] and murine osteoblastic cells [32, 35], and increased Jagged1 in human stroma is sufficient to expand HSC [60]. Additionally Jagged1 is expressed by human derived mesenchymal-like CD146+ cells which can form a hematopoietic supportive niche [61]. Although the functionality of Jagged1 in these cells was not examined this provides further evidence of the involvement of Notch signaling in the niche. Our own work also implicated Notch signaling in the parathyroid hormone (PTH) mediated increase of HSC by osteoblastic cells [10]. Mice with a constitutively active PTH receptor expressed in osteoblastic cells [62] had an increase in osteoblastic Jagged1, increased HSC NICD levels, and increased numbers of HSCs [10]. The results could also be replicated with PTH injections [10]. We and others have also found that PTH administration leads to an increase in Jagged1 both in vivo and in vitro[35, 63]. Further in vitro studies suggested that the PTH-dependent HSC increase requires direct contact of stroma and HSC [10]. Moreover, this increase could be abrogated by administration of a γ-secretase inhibitor [10]. Together, these in vitro data are consistent with an important role of Notch in niche regulation of HSC behavior. As constitutively active PTH receptor mice only have an altered receptor in osteoblastic cells, and HSC do not express the PTH receptor [64] the response of HSC to PTH must be initiated by osteoblastic cells, however the differentiation stage of these HSC-supportive osteoblastic cells is currently unknown.
In contrast to these studies, others have reported that Jagged1 and Notch signaling are not important for maintaining HSC populations. Mancini et al. generated a Jagged1 floxed (fl/fl) mouse and bred it to the interferon inducibile Mx1 cre mice [65, 66]. After cre induction, the basal levels of HSC were not significantly different from the control animals. The same was true when using the induced Mx1 cre in combination with the Notch1 fl/fl animal or the combination of Jagged1 fl/fl/Notch1fl/fl. Mx1 cre Notch1 fl/fl HSC were transplanted into Mx1 cre Jagged1 fl/fl mice and had similar basal levels to control HSC after induction of the cre. This study suggests that Notch signaling is not necessary in maintaining HSC in basal conditions. Additionally, only Jagged1 and Notch1 were removed in the experimental conditions and other Notch signaling elements could be compensating for their loss. Following this publication, Maillard et al. developed a dominant negative Mastermind-like1 (dnMAML) which binds to the activated NICD and inhibits Notch 1–4 from signaling [67]. Whether dnMAML was transfected into LSK or if the LSK came from genetically altered animals, these cells reconstituted the bone marrow equally to cells from controls, except for changes in T-cells which would be expected with models affecting Notch signaling. They also found no difference after secondary transplantation suggesting that the long term repopulating capabilities of HSC and the LT-HSC population do not require Notch signaling. These results were confirmed with Mx1 cre RBPJ fl/fl, where RBPJ encodes for a DNA-binding factor that is necessary for signaling of all Notch receptors. The models used in this study rule out the possibility of compensation by alternative Notch receptors as all Notch signaling is removed and they still do not see a change in basal HSC or reconstitution ability. Both of these studies indicate that Notch signaling is not necessary for the maintenance of HSC at steady state and in some situations of myeloablative injury.
In contrast to the latter studies, evidence that Notch in the microenvironment is important for normal hematopoiesis was recently provided by Kim et al. [68]. In these experiments, inactivation of Mind bomb-1 (Mib1), which is essential for Notch ligand endocytosis and Notch activation, resulted in the development of myeloproliferative disease (MPD). The surprising finding was that transplantation of wild-type bone marrow cells into the Mib-1 null microenvironment resulted in de novo MPD. Activated N1ICD cells were also transplanted into the Mib1 null microenvironment which significantly slowed progression of the MPD [68]. These results suggest that the MPD resulted from the non-hematopoietic microenvironmental cells with defective Notch signaling. These experiments demonstrate that Notch signaling in the microenvironment does play a role in maintaing normal hematopoiesis.
Although the verdict is still out on the role of Notch in HSC maintenance, it is evident from in vitro studies that Notch ligands can increase HSC and maintain progenitor populations. It is also appears that normal Notch signaling in the bone marrow microenvironment is necessary to maintain normal hematopoiesis. Based on the data available so far, it is unlikely that Notch signaling is the only pathway to regulate HSC within the niche. Many other pathways, such as N-cadherin [50], Angiopoietin1/Tie2 [69], Osteopontin [70, 71], Annexin II [72] and Wnt [73] have been implicated in HSC regulation by the osteoblastic niche. Removing only one of these and looking at basal levels may not be enough to definitively determine the role of the pathway and may explain some of the varied results that have been presented to date.
Further studies are necessary to determine the roles of Notch signaling throughout osteoblastic maturation and the effects of Notch on bone maintenance. This will require removing or activating Notch signaling at maturation stages to determine how Notch is acting as it can cause self renewal, binary fate decisions, or terminal differentiation. However, given the roles identified for Notch in both osteoblastic and hematopoietic cells, it is likely that Notch is an important regulator of hematopoietic osteoblastic regulatory interactions. Notch can therefore potentially be regarded as a target for pharmacological expansion of HSC in situations of clinical need, such as in the recovery from environmental or iatrogenic myeloablation.
Acknowledgments
This work was supported by the National Institutes of Health, National Institute of Diabetes, Digestive and Kidney Diseases (K08 DK064381, R21 DK069563, R01 DK 076876 to L.M.C.), the Wilmot Cancer Scholar Foundation (L.M.C.) and the Pew Foundation (L.M.C.). J.M.W. is supported by T32 AR05345903. The authors thank Matthew J. Hilton, Benjamin J. Frisch and Rebecca L. Porter for their helpful discussions.
Footnotes
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
1. Schofield R. The relationship between the spleen colony-forming cell and the haemopoietic stem cell. Blood Cells. 1978;4:7–25. [PubMed]
2. Spradling A, Drummond-Barbosa D, Kai T. Stem cells find their niche. Nature. 2001;414:98–104. [PubMed]
3. Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science. 1999;284:770–6. [PubMed]
4. Porter RL, Calvi LM. Communications between bone cells and hematopoietic stem cells. Arch Biochem Biophys. 2008;473:193–200. [PMC free article] [PubMed]
5. Taichman RS, Emerson SG. The role of osteoblasts in the hematopoietic microenvironment. Stem Cells. 1998;16:7–15. [PubMed]
6. Reynolds TC, Smith SD, Sklar J. Analysis of DNA surrounding the breakpoints of chromosomal translocations involving the beta T cell receptor gene in human lymphoblastic neoplasms. Cell. 1987;50:107–17. [PubMed]
7. Ellisen LW, Bird J, West DC, Soreng AL, Reynolds TC, Smith SD, Sklar J. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell. 1991;66:649–61. [PubMed]
8. Engin F, Yao Z, Yang T, Zhou G, Bertin T, Jiang MM, Chen Y, Wang L, Zheng H, Sutton RE, Boyce BF, Lee B. Dimorphic effects of Notch signaling in bone homeostasis. Nat Med. 2008;14:299–305. [PMC free article] [PubMed]
9. Hilton MJ, Tu X, Wu X, Bai S, Zhao H, Kobayashi T, Kronenberg HM, Teitelbaum SL, Ross FP, Kopan R, Long F. Notch signaling maintains bone marrow mesenchymal progenitors by suppressing osteoblast differentiation. Nat Med. 2008;14:306–14. [PMC free article] [PubMed]
10. Calvi LM, Adams GB, Weibrecht KW, Weber JM, Olson DP, Knight MC, Martin RP, Schipani E, Divieti P, Bringhurst FR, Milner LA, Kronenberg HM, Scadden DT. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature. 2003;425:841–6. [PubMed]
11. Baron M. An overview of the Notch signalling pathway. Semin Cell Dev Biol. 2003;14:113–9. [PubMed]
12. Fortini ME. Gamma-secretase-mediated proteolysis in cell-surface-receptor signalling. Nat Rev Mol Cell Biol. 2002;3:673–84. [PubMed]
13. Hsieh JJ, Zhou S, Chen L, Young DB, Hayward SD. CIR, a corepressor linking the DNA binding factor CBF1 to the histone deacetylase complex. Proc Natl Acad Sci U S A. 1999;96:23–8. [PubMed]
14. Kao HY, Ordentlich P, Koyano-Nakagawa N, Tang Z, Downes M, Kintner CR, Evans RM, Kadesch T. A histone deacetylase corepressor complex regulates the Notch signal transduction pathway. Genes Dev. 1998;12:2269–77. [PubMed]
15. Zhou S, Fujimuro M, Hsieh JJ, Chen L, Miyamoto A, Weinmaster G, Hayward SD. SKIP, a CBF1-associated protein, interacts with the ankyrin repeat domain of NotchIC To facilitate NotchIC function. Mol Cell Biol. 2000;20:2400–10. [PMC free article] [PubMed]
16. Wu L, Aster JC, Blacklow SC, Lake R, Artavanis-Tsakonas S, Griffin JD. MAML1, a human homologue of Drosophila mastermind, is a transcriptional co-activator for NOTCH receptors. Nat Genet. 2000;26:484–9. [PubMed]
17. Jeffries S, Robbins DJ, Capobianco AJ. Characterization of a high-molecular-weight Notch complex in the nucleus of Notch(ic)-transformed RKE cells and in a human T-cell leukemia cell line. Mol Cell Biol. 2002;22:3927–41. [PMC free article] [PubMed]
18. Pear WS, Aster JC, Scott ML, Hasserjian RP, Soffer B, Sklar J, Baltimore D. Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles. J Exp Med. 1996;183:2283–91. [PMC free article] [PubMed]
19. Deftos ML, Huang E, Ojala EW, Forbush KA, Bevan MJ. Notch1 signaling promotes the maturation of CD4 and CD8 SP thymocytes. Immunity. 2000;13:73–84. [PMC free article] [PubMed]
20. Bellavia D, Campese AF, Alesse E, Vacca A, Felli MP, Balestri A, Stoppacciaro A, Tiveron C, Tatangelo L, Giovarelli M, Gaetano C, Ruco L, Hoffman ES, Hayday AC, Lendahl U, Frati L, Gulino A, Screpanti I. Constitutive activation of NF-kappaB and T-cell leukemia/lymphoma in Notch3 transgenic mice. EMBO J. 2000;19:3337–48. [PubMed]
21. Weng AP, Ferrando AA, Lee W, Morris JPt, Silverman LB, Sanchez-Irizarry C, Blacklow SC, Look AT, Aster JC. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004;306:269–71. [PubMed]
22. Laky K, Fowlkes BJ. Notch signaling in CD4 and CD8 T cell development. Curr Opin Immunol. 2008;20:197–202. [PMC free article] [PubMed]
23. Fu L, Kogoshi H, Nara N, Tohda S. NOTCH1 mutations are rare in acute myeloid leukemia. Leuk Lymphoma. 2006;47:2400–3. [PubMed]
24. Zhou L, Li LW, Yan Q, Petryniak B, Man Y, Su C, Shim J, Chervin S, Lowe JB. Notch-dependent control of myelopoiesis is regulated by fucosylation. Blood. 2008;112:308–19. [PubMed]
25. Radtke F, Wilson A, MacDonald HR. Notch signaling in hematopoiesis and lymphopoiesis: lessons from Drosophila. Bioessays. 2005;27:1117–28. [PubMed]
26. Ohishi K, Katayama N, Shiku H, Varnum-Finney B, Bernstein ID. Notch signalling in hematopoiesis. Semin Cell Dev Biol. 2003;14:143–50. [PubMed]
27. Varnum-Finney B, Xu L, Brashem-Stein C, Nourigat C, Flowers D, Bakkour S, Pear WS, Bernstein ID. Pluripotent, cytokine-dependent, hematopoietic stem cells are immortalized by constitutive Notch1 signaling. Nat Med. 2000;6:1278–81. [PubMed]
28. Stier S, Cheng T, Dombkowski D, Carlesso N, Scadden DT. Notch1 activation increases hematopoietic stem cell self-renewal in vivo and favors lymphoid over myeloid lineage outcome. Blood. 2002;99:2369–78. [PubMed]
29. Duncan AW, Rattis FM, DiMascio LN, Congdon KL, Pazianos G, Zhao C, Yoon K, Cook JM, Willert K, Gaiano N, Reya T. Integration of Notch and Wnt signaling in hematopoietic stem cell maintenance. Nat Immunol. 2005;6:314–22. [PubMed]
30. Wu M, Kwon H, Rattis F, Blum J, Zhao C, Ashkenazi R, Jackson T, Gaiano N, Oliver T, Reya T. Imaging Hematopoietic Precursor Division in Real Time. Cell Stem Cell. 2007;1:541–554. [PMC free article] [PubMed]
31. Kessler CB, Delany AM. Increased Notch 1 expression and attenuated stimulatory G protein coupling to adenylyl cyclase in osteonectin-null osteoblasts. Endocrinology. 2007;148:1666–74. [PubMed]
32. Pereira RM, Delany AM, Durant D, Canalis E. Cortisol regulates the expression of Notch in osteoblasts. J Cell Biochem. 2002;85:252–8. [PubMed]
33. Sciaudone M, Gazzerro E, Priest L, Delany AM, Canalis E. Notch 1 impairs osteoblastic cell differentiation. Endocrinology. 2003;144:5631–9. [PubMed]
34. Nobta M, Tsukazaki T, Shibata Y, Xin C, Moriishi T, Sakano S, Shindo H, Yamaguchi A. Critical regulation of bone morphogenetic protein-induced osteoblastic differentiation by Delta1/Jagged1-activated Notch1 signaling. J Biol Chem. 2005;280:15842–8. [PubMed]
35. Weber JM, Forsythe SR, Christianson CA, Frisch BJ, Gigliotti BJ, Jordan CT, Milner LA, Guzman ML, Calvi LM. Parathyroid hormone stimulates expression of the Notch ligand Jagged1 in osteoblastic cells. Bone. 2006;39:485–93. [PubMed]
36. Smerdel-Ramoya A, Zanotti S, Deregowski V, Canalis E. Connective tissue growth factor enhances osteoblastogenesis in vitro. J Biol Chem. 2008;283:22690–9. [PubMed]
37. Shindo K, Kawashima N, Sakamoto K, Yamaguchi A, Umezawa A, Takagi M, Katsube K, Suda H. Osteogenic differentiation of the mesenchymal progenitor cells, Kusa is suppressed by Notch signaling. Exp Cell Res. 2003;290:370–80. [PubMed]
38. Deregowski V, Gazzerro E, Priest L, Rydziel S, Canalis E. Role of the RAM domain and ankyrin repeats on notch signaling and activity in cells of osteoblastic lineage. J Bone Miner Res. 2006;21:1317–26. [PubMed]
39. Zanotti S, Smerdel-Ramoya A, Stadmeyer L, Durant D, Radtke F, Canalis E. Notch inhibits osteoblast differentiation and causes osteopenia. Endocrinology. 2008;149:3890–9. [PubMed]
40. Tezuka K, Yasuda M, Watanabe N, Morimura N, Kuroda K, Miyatani S, Hozumi N. Stimulation of osteoblastic cell differentiation by Notch. J Bone Miner Res. 2002;17:231–9. [PubMed]
41. Watanabe N, Tezuka Y, Matsuno K, Miyatani S, Morimura N, Yasuda M, Fujimaki R, Kuroda K, Hiraki Y, Hozumi N, Tezuka K. Suppression of differentiation and proliferation of early chondrogenic cells by Notch. J Bone Miner Metab. 2003;21:344–52. [PubMed]
42. Donoviel DB, Hadjantonakis AK, Ikeda M, Zheng H, Hyslop PS, Bernstein A. Mice lacking both presenilin genes exhibit early embryonic patterning defects. Genes Dev. 1999;13:2801–10. [PubMed]
43. Bolos V, Grego-Bessa J, de la Pompa JL. Notch signaling in development and cancer. Endocr Rev. 2007;28:339–63. [PubMed]
44. Yamada T, Yamazaki H, Yamane T, Yoshino M, Okuyama H, Tsuneto M, Kurino T, Hayashi S, Sakano S. Regulation of osteoclast development by Notch signaling directed to osteoclast precursors and through stromal cells. Blood. 2003;101:2227–34. [PubMed]
45. Bai S, Kopan R, Zou W, Hilton MJ, Ong CT, Long F, Ross FP, Teitelbaum SL. NOTCH1 regulates osteoclastogenesis directly in osteoclast precursors and indirectly via osteoblast lineage cells. J Biol Chem. 2008;283:6509–18. [PubMed]
46. McGovern M, Voutev R, Maciejowski J, Corsi AK, Hubbard EJ. A “latent niche” mechanism for tumor initiation. Proc Natl Acad Sci U S A. 2009;106:11617–22. [PubMed]
47. Song X, Call GB, Kirilly D, Xie T. Notch signaling controls germline stem cell niche formation in the Drosophila ovary. Development. 2007;134:1071–80. [PubMed]
48. Ward EJ, Shcherbata HR, Reynolds SH, Fischer KA, Hatfield SD, Ruohola-Baker H. Stem cells signal to the niche through the Notch pathway in the Drosophila ovary. Curr Biol. 2006;16:2352–8. [PubMed]
49. Boni A, Urbanek K, Nascimbene A, Hosoda T, Zheng H, Delucchi F, Amano K, Gonzalez A, Vitale S, Ojaimi C, Rizzi R, Bolli R, Yutzey KE, Rota M, Kajstura J, Anversa P, Leri A. Notch1 regulates the fate of cardiac progenitor cells. Proc Natl Acad Sci U S A. 2008;105:15529–34. [PubMed]
50. Zhang J, Niu C, Ye L, Huang H, He X, Tong WG, Ross J, Haug J, Johnson T, Feng JQ, Harris S, Wiedemann LM, Mishina Y, Li L. Identification of the haematopoietic stem cell niche and control of the niche size. Nature. 2003;425:836–41. [PubMed]
51. Visnjic D, Kalajzic Z, Rowe DW, Katavic V, Lorenzo J, Aguila HL. Hematopoiesis is severely altered in mice with an induced osteoblast deficiency. Blood. 2004;103:3258–64. [PubMed]
52. Colmone A, Sipkins DA. Beyond angiogenesis: the role of endothelium in the bone marrow vascular niche. Transl Res. 2008;151:1–9. [PubMed]
53. Karanu FN, Murdoch B, Gallacher L, Wu DM, Koremoto M, Sakano S, Bhatia M. The notch ligand jagged-1 represents a novel growth factor of human hematopoietic stem cells. J Exp Med. 2000;192:1365–72. [PMC free article] [PubMed]
54. Karanu FN, Yuefei L, Gallacher L, Sakano S, Bhatia M. Differential response of primitive human CD34− and CD34+ hematopoietic cells to the Notch ligand Jagged-1. Leukemia. 2003;17:1366–74. [PubMed]
55. Karanu FN, Murdoch B, Miyabayashi T, Ohno M, Koremoto M, Gallacher L, Wu D, Itoh A, Sakano S, Bhatia M. Human homologues of Delta-1 and Delta-4 function as mitogenic regulators of primitive human hematopoietic cells. Blood. 2001;97:1960–7. [PubMed]
56. Varnum-Finney B, Purton LE, Yu M, Brashem-Stein C, Flowers D, Staats S, Moore KA, Le Roux I, Mann R, Gray G, Artavanis-Tsakonas S, Bernstein ID. The Notch ligand, Jagged-1, influences the development of primitive hematopoietic precursor cells. Blood. 1998;91:4084–91. [PubMed]
57. Varnum-Finney B, Brashem-Stein C, Bernstein ID. Combined effects of Notch signaling and cytokines induce a multiple log increase in precursors with lymphoid and myeloid reconstituting ability. Blood. 2003;101:1784–9. [PubMed]
58. Carlesso N, Aster JC, Sklar J, Scadden DT. Notch1-induced delay of human hematopoietic progenitor cell differentiation is associated with altered cell cycle kinetics. Blood. 1999;93:838–48. [PubMed]
59. Ohishi K, Varnum-Finney B, Bernstein ID. Delta-1 enhances marrow and thymus repopulating ability of human CD34(+)CD38(−) cord blood cells. J Clin Invest. 2002;110:1165–74. [PMC free article] [PubMed]
60. Li L, Milner LA, Deng Y, Iwata M, Banta A, Graf L, Marcovina S, Friedman C, Trask BJ, Hood L, Torok-Storb B. The human homolog of rat Jagged1 expressed by marrow stroma inhibits differentiation of 32D cells through interaction with Notch1. Immunity. 1998;8:43–55. [PubMed]
61. Sacchetti B, Funari A, Michienzi S, Di Cesare S, Piersanti S, Saggio I, Tagliafico E, Ferrari S, Robey PG, Riminucci M, Bianco P. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell. 2007;131:324– 36. [PubMed]
62. Calvi LM, Sims NA, Hunzelman JL, Knight MC, Giovannetti A, Saxton JM, Kronenberg HM, Baron R, Schipani E. Activated parathyroid hormone/parathyroid hormone-related protein receptor in osteoblastic cells differentially affects cortical and trabecular bone. J Clin Invest. 2001;107:277–86. [PMC free article] [PubMed]
63. Qin L, Qiu P, Wang L, Li X, Swarthout JT, Soteropoulos P, Tolias P, Partridge NC. Gene expression profiles and transcription factors involved in parathyroid hormone signaling in osteoblasts revealed by microarray and bioinformatics. J Biol Chem. 2003;278:19723–31. [PubMed]
64. Adams GB, Martin RP, Alley IR, Chabner KT, Cohen KS, Calvi LM, Kronenberg HM, Scadden DT. Therapeutic targeting of a stem cell niche. Nat Biotechnol. 2007;25:238–43. [PubMed]
65. Kuhn R, Schwenk F, Aguet M, Rajewsky K. Inducible gene targeting in mice. Science. 1995;269:1427–9. [PubMed]
66. Mancini SJ, Mantei N, Dumortier A, Suter U, MacDonald HR, Radtke F. Jagged1-dependent Notch signaling is dispensable for hematopoietic stem cell self-renewal and differentiation. Blood. 2005;105:2340–2. [PubMed]
67. Maillard I, Koch U, Dumortier A, Shestova O, Xu L, Sai H, Pross SE, Aster JC, Bhandoola A, Radtke F, Pear WS. Canonical notch signaling is dispensable for the maintenance of adult hematopoietic stem cells. Cell Stem Cell. 2008;2:356–66. [PubMed]
68. Kim YW, Koo BK, Jeong HW, Yoon MJ, Song R, Shin J, Jeong DC, Kim SH, Kong YY. Defective Notch activation in microenvironment leads to myeloproliferative disease. Blood. 2008;112:4628–38. [PubMed]
69. Arai F, Hirao A, Ohmura M, Sato H, Matsuoka S, Takubo K, Ito K, Koh GY, Suda T. Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell. 2004;118:149–61. [PubMed]
70. Nilsson SK, Johnston HM, Whitty GA, Williams B, Webb RJ, Denhardt DT, Bertoncello I, Bendall LJ, Simmons PJ, Haylock DN. Osteopontin, a key component of the hematopoietic stem cell niche and regulator of primitive hematopoietic progenitor cells. Blood. 2005;106:1232–9. [PubMed]
71. Stier S, Ko Y, Forkert R, Lutz C, Neuhaus T, Grunewald E, Cheng T, Dombkowski D, Calvi LM, Rittling SR, Scadden DT. Osteopontin is a hematopoietic stem cell niche component that negatively regulates stem cell pool size. J Exp Med. 2005;201:1781–91. [PMC free article] [PubMed]
72. Jung Y, Wang J, Song J, Shiozawa Y, Havens A, Wang Z, Sun YX, Emerson SG, Krebsbach PH, Taichman RS. Annexin II expressed by osteoblasts and endothelial cells regulates stem cell adhesion, homing, and engraftment following transplantation. Blood. 2007;110:82–90. [PubMed]
73. Reya T, Duncan AW, Ailles L, Domen J, Scherer DC, Willert K, Hintz L, Nusse R, Weissman IL. A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature. 2003;423:409–14. [PubMed]